RESUMO
Primary amyloidosis is a rare condition characterised by the deposition of free light chains in different tissues and organs (e.g. kidney, heart, liver, gastrointestinal system). The aim of the therapy in patients with primary amyloidosis is to suppress the monoclonal plasma cells that produce the amyloidogenic free light chains and to preserve the organ function. Thus, the new criteria for the haematological disease response include the measurement of serum free light chains concentrations. The case is presented on a patient diagnosed with primary amyloidosis, where the difference between bound and free serum free light chains (dFLC) was used to evaluate the haematological response to the treatment, as well as any biological progression. In contrast to dFLC, Bence Jones Protein in urine was positive but ineffective to evaluate the response to the treatment (AU)
La amiloidosis primaria es una entidad rara caracterizada por el depósito de cadenas ligeras libres en diferentes tejidos y órganos (riñón, corazón, hígado, aparato gastrointestinal). El objetivo en la terapia de los pacientes con amiloidosis primaria consiste en suprimir las células plasmáticas monoclonales que producen las cadenas ligeras libres amiloidogénicas y preservar la función de los órganos afectados. Así, los nuevos criterios de respuesta hematológica de la enfermedad incorporan la medida de las concentraciones séricas de cadenas ligeras libres. Presentamos el caso de una paciente a quien se diagnosticó amiloidosis primaria y en la cual la diferencia de concentración en suero entre la cadena ligera libre monoclonal implicada y la no implicada (dFLC) nos permitió evaluar la respuesta hematológica al tratamiento y la presencia de progresión biológica. En contraste a la dFLC, la proteinuria de Bence Jones fue positiva pero ineficaz en la evaluación de la respuesta al tratamiento (AU)
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Amiloidose/diagnóstico , Amiloidose/patologia , Proteína de Bence Jones/administração & dosagem , Proteína de Bence Jones/análise , Plasmócitos/citologia , Plasmócitos/patologia , Proteína de Bence Jones/genética , PlasmócitosRESUMO
The role of Bence Jones proteins (BJPs) in the genesis of the renal dysfunction that develops in patients with multiple myeloma is not clearly defined. We previously evaluated renal function and morphology in a unique strain of rats (LOU/m) bearing tumors which synthesized BJPs with isoelectric points of 5.2, 4.3 and 6.7. Myeloma cast nephropathy developed in one tumor bearing group (pI 5.2), tubular necrosis was observed in another (pI 4.3), and renal function and histology remained normal in a third group (pI 6.7). To see if these renal outcomes were a function of the BJP being excreted or other factors which could be present in the tumor bearing animals, we have examined the effect of chronic intravenous administration of these three BJPs on renal function and histology in non-tumor-bearing LOU/m rats. Urine containing the BJP was collected from tumor bearing rats, sterilized by passage through a 0.2 mu millipore filter, concentrated to 50 mg/ml, and dialyzed extensively so as to remove material with a molecular weight less than 3500. Chronic indwelling-venous catheters were placed in non-tumor-bearing LOU/m rats and these rats were given 100 mg/day for five days of one of the three BJPs. Polyfructosan clearance (Cin) was measured prior to and following the five days of BJP administration. Renal histology was examined at the completion of the second Cin. In the pI 5.2 group (N = 6), a severe distal nephron cast nephropathy occurred and Cin fell from 2.88 +/- 0.24 to 0.90 +/- 0.17 ml/min (P less than 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)